AbbVie (NYSE:ABBV) recently announced the availability of its drug SKYRIZI® in Canada for treating adults with ulcerative ...

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation ...

AbbVie Inc. ( NYSE: ABBV) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R. Stewart - Executive ...

We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...